According to Ars Technica, an FDA rejection of UniQure's gene therapy—widely criticized as controversial—was overturned after the departure of the Trump administration official involved in the decision. The company subsequently received another FDA meeting.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton